Список литературы

1. Давыдов М.И. Энциклопедия клинической онкологии. М.: ООО "РЛС2004"; 2004.

2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(R)). Cancer of the Nasopharynx. Version 1.2020.

3. Гурцевич В.Э., Сенюта Н.Б., Кондратова В.Н., Гончарова Е.В., Игнатова А.В., Ломая М.В., Кропотов М.А., Мудунов А.М., Лихтенштейн А.В. Диагностическая значимость уровней ДНК и антител к капсидному антигену вируса Эпштейна-Барра в плазме крови больных раком носоглотки в неэндемическом регионе. Успехи молекулярной онкологии 2015; 2(2): 56 - 62.

4. Global Cancer Obserbvatory. Cancer Today. URL:http://gco.iarc.fr.

5. Алиева С.Б., Алымов Ю.В., Кропотов М.А., Мудунов А.М., Подвязников С.О. Рак гортани. Онкология. Клинические рекомендации. Под ред. М.И. Давыдова. М.: Издательская группа РОНЦ; 2015. Стр. 209 - 212.

6. Lo Y.M., Chan L.Y., Lo K.W., Leung S.F., Zhang J., Chan A.T. et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999; 59(6): 1188 - 1191

7. Dogan S., Hedberg M.L., Ferris R.L. et al. Human papillomavirus and Epstein-Barr virus in nasopharyngeal carcinoma in a low-incidence population. Head Neck 2014; 36: 511 - 516.

8. Zhang W., Chen Y., Chen L. et al. The clinical utility of plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma: the dawn of a new era?: a systematic review and meta-analysis of 7836 cases. Medicine (Baltimore) 2015; 94:e845.

9. Lin J.C., Wang W.Y., Chen K.Y. et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004; 350: 2461 - 2470.

10. Lin J.C., Wang W.Y., Liang W.M. et al. Long-term prognostic effects of plasma Epstein-Barr virus DNA by minor groove binder-probe real-time quantitative; PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007; 68: 1342 - 1348.

11. Prayongrat A., Chakkabat C., Kannarunimit D. et al. Prevalence and significance of plasma Epstein-Barr Virus DNA level in nasopharyngeal carcinoma. J Radiat Res 2017; 58: 509 - 516.

12. Leung S.F., Chan A.T., Zee B. et al. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Cancer 2003; 98: 288 - 291.

13. Leung S.F., Chan K.C., Ma B.B. et al. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. Ann Oncol 2014; 25: 1204 - 1208.

14. Gulley M.L. Molecular diagnosis of Epstein-Barr virus-related diseases. J Mol Diagn 2001; 3: 1 - 10.

15. Fleming AJ, Jr., Smith SP, Jr., Paul CM, et al. Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients. Laryngoscope 2007; 117: 1173 - 79.

16. Blanchard P., Lee A., Marguet S. et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol 2015; 16: 645 - 655.

17. Zhang Y., Li W.F., Liu X. et al. Nomogram to predict the benefit of additional induction chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Analysis of a multicenter, phase III randomized trial. Radiother Oncol 2017.

18. Ribassin-Majed L., Marguet S., Lee A.W. et al. What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis. J Clin Oncol 2016: Jco2016674119.

19. Jin Y., Cai X.Y., Shi Y.X. et al. Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma. J Cancer Res Clin Oncol 2012 Oct; 138(10): 1717 - 25.

20. Zhang L., Huang Y., Hong S. et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet 2016; 388: 1883 - 1892.

21. Lee N., Xia P., Quivey J.M., Sultanem K. et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 2002 May 1; 53(1): 12 - 22.

22. Laskar S., Bahl G., Muckaden M., Pai S.K., Gupta T., Banavali S. et al. Nasopharyngeal carcinoma in children: comparison of conventional and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2008 Nov 1; 72(3): 728 - 36.

23. Taheri-Kadkhoda Z, Bjork-Eriksson T, Nill S, et al. Intensity modulated radiotherapy of nasopharyngeal carcinoma: A comparative treatment planning study of photons and protons//Radiat Oncol. 2008. Vol. 3. P. 4.

24. Терапевтическая радиология: национальное руководство. Под ред. А.Д. Каприна, Ю.С. Мардынского. М.: ГЭОТАР-Медиа, 2018.

25. Болотина Л.В., Владимирова Л.Ю., Деньгина Н.В., Новик А.В., Романов И.С. Практические рекомендации по лечению злокачественных опухолей головы и шеи//Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2018 (том 8). С. 71 - 82.

26. Jae-Sook Ahn, Sang-Hee Cho, Ok-Ki Kim et al. The Efficacy of an Induction Chemotherapy Combination with Docetaxel, Cisplatin, and 5-FU Followed by Concurrent Chemoradiotherapy in Advanced Head and Neck Cancer. Cancer Res Treat. 2007 Sep; 39(3): 93 - 98.

27. Lee, A. W. M., Tung, S. Y., Ng et al. (2017). A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity. Cancer, 123(21), 4147 - 4157.

28. Schoffski, P., Catimel, G., Planting et al. (1999). Docetaxel and cisplatin: An active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Annals of Oncology, 10(1), 119 - 122.

29. Gibson, M. K., Li, Y., Murphy, B., Hussain, M. H. A., DeConti, R. C., Ensley, J., & Forastiere, A. A. (2005). Randomized Phase III Evaluation of Cisplatin Plus Fluorouracil Versus Cisplatin Plus Paclitaxel in Advanced Head and Neck Cancer (E1395): An Intergroup Trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 23(15), 3562 - 3567.

30. Jacobs, C., Lyman, G., Velez-Garcia, E. et al (1992). A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. Journal of Clinical Oncology, 10(2), 257 - 263.

31. Grau, J. jose, Caballero, M., et al (2009). Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients. Acta Oto-Laryngologica, 129(11), 1294 - 1299.

32. Catimel, G., Verweij, J., Mattijssen, V., et al (1994). Docetaxel (Taxotere(R)): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Annals of Oncology, 5(6), 533 - 537.

33. Guardiola, E., Peyrade, F., Chaigneau, L. et al (2004). Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. European Journal of Cancer, 40(14), 2071 - 2076.

34. Martinez-Trufero J., Isla D., Adansa J.C. et al. Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. Br J Cancer 2010; 102: 1687 - 91.

35. Seiwert T.Y., Burtness B., Mehra R. et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 2016; 17: 956 - 965.

36. Chow L.Q., Haddad R., Gupta S. et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and / or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol 2016; 34: 3838 - 3845.

37. Hsu C., Lee S.H., Ejadi S. et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study. J Clin Oncol 2017; 35: 4050 - 4056.

38. Clarke P., Radford K., Coffey M., Stewart M. Speech and swallow rehabilitation in head and neck cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol 2016; 130(S2): S176 - 80.

39. Сытов А.В., Лейдерман И.Н., Ломидзе С.В., Нехаев И.В., Хотеев А.Ж. Практические рекомендации по нутритивной поддержке онкологических больных//Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2018 (том 8). С. 575 - 583.

40. Zhao, S. G., Alexander, N. B., Djuric, Z., et al (2015). Maintaining physical activity during head and neck cancer treatment: Results of a pilot controlled trial. Head & Neck, 38(S1), E1086 - E1096.

41. Segal R., Zwaal C., Green E. et al. Exercise for people with cancer: a systematic review. Curr Oncol. 2017 Aug; 24(4): e290 - e31.

42. Samuel S.R., Maiya G.A., Fernandes D.J. et al. Effectiveness of exercise-based rehabilitation on functional capacity and quality of life in head and neck cancer patients receiving chemo-radiotherapy. Support Care Cancer 2019.

43. Mustian K.M., Alfano C.M., Heckler C. et al: Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol 2017; 3: 961 - 8.

44. Kinkead B., Schettler P.J., Larson E.R. et al. Massage therapy decreases cancer-related fatigue: results from a randomized early phase trial. Cancer 2018; 124(3): 546 - 54.

45. Streckmann F., Zopf E.M., Lehmann H.C. et al: Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med 2014; 44: 1289 - 304.

46. Lee J.M., Look R.M., Turner C. et al. Low-level laser therapy for chemotherapy-induced peripheral neuropathy. J Clin Oncol 2012; 30(15): 9019.

47. Rick O., von Hehn U., Mikus E. et al. Magnetic field therapy in patients with cytostatics-induced polyneuropathy: a prospective randomized placebo-controlled phase-III study. Bioelectromagnetics 2016: 38(2): 85 - 94.

48. Oberoi S., Zamperlini-Netto G., Beyene J. et al. Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis. PLoS One 2014; 9(9): e107418.

49. He M., Zhang B., Shen N., Wu N., Sun J. A systematic review and meta-analysis of the effect of low-level laser therapy (LLLT) on chemotherapy-induced oral mucositis in pediatric and young patients. Eur J Pediatr 2018; 177(1): 7 - 17.

50. Ross M., Fischer-Cartlidge E. Scalp cooling: a literature review of efficacy, safety, and tolerability for chemotherapy-induced alopecia. Clin J Oncol Nurs 2017; 21(2): 226 - 33.

51. Avci P., Gupta G.K., Clark J. et al. Low-level laser (light) therapy (LLLT) for treatment of hair loss. Lasers Surg Med 2013; 46(2): 144 - 51.

52. Bensadoun R.J., Nair R.G. Low-level laser therapy in the management of mucositis and dermatitis induced by cancer therapy. Photomed Laser Surg 2015; 33(10): 487 - 91.

53. Roopashri G. Radiotherapy and chemotherapy induced oral mucositis - prevention and current therapeutic modalities. IJDA 2010; 2: 174 - 9.

54. Сопроводительная терапия в онкологии. Практическое руководство. Под ред. С.Ю. Мооркрафта, Д.Л.Ю. Ли, Д. Каннингэма. Пер. с англ. Под ред. А.Д. Каприна. М.: Гэотар, 2016. 432 с.

55. Rosenthal D.I., Trotti A. Strategies for managing radiation-induced mucositis in head and neck cancer. Semin Radiat Oncol 2009; 19: 29 - 34.

56. Pauloski B.R. Rehabilitation of dysphagia following head and neck cancer. Phys Med Rehabil Clin N Am 2008; 9: 889 - 928.